Market Overview

Intercept Pharma Begins Phase 2 NASH Trial of OCA in Japan

Share:
Related ICPT
Calls Of Note: Wall Street Research Moving The Market On Thursday
Pipeline Updates Make These Three Biotech Stocks Worth Watching

Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver diseases, today announced that its partner Dainippon Sumitomo Pharma (DSP) has initiated a phase 2 clinical trial of obeticholic acid (OCA) in adult nonalcoholic steatohepatitis (NASH) patients in Japan.

The trial is studying the efficacy and safety of a once daily dose of OCA, with the goal of randomizing 200 NASH patients to receiving OCA or placebo. The primary endpoint will be evaluated by histological improvement. DSP expects to complete the trial in the first half of 2016.

Posted-In: News FDA

 

Related Articles (ICPT)

View Comments and Join the Discussion!

Get Benzinga's Newsletters